Johnson & Johnson’s Tremfya Gains FDA Approval for Crohn’s Disease Treatment
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced receiving clearance from the...
Menarini Group Partners with VisualDx to Enhance BPDCN Identification Using AI/ML Tools
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has formed a partnership with US-based...
Elevation Oncology Halts EO-3021 Development After Poor Phase 1 Data
US-based Elevation Oncology, Inc. (NASDAQ: ELEV) has announced the decision to terminate development of EO-3021...
Changchun High & New Technology Industries Receives US Trial Approval for GenSci120 in Rheumatoid Arthritis
China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced its subsidiary GenScipt...
Novartis’ Fabhalta Approved by FDA for C3 Glomerulopathy Treatment
Swiss pharmaceutical giant Novartis’ (NYSE: NVS) iptacopan, marketed as Fabhalta, has received approval from the...
Sino Biopharmaceutical’s 2024 Revenue Up 10.2% on Strong Innovative Drug Sales
China-based Sino Biopharmaceutical Ltd (HKG: 1177) released its 2024 financial report, recording revenues of RMB...
Arcutis Biotherapeutics’ Zoryve Cream Nears FDA Approval for Pediatric Atopic Dermatitis
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its US partner Arcutis Biotherapeutics, Inc....
Sanofi to Acquire DR-0201 for $600 Million to Advance Myeloid Cell Engager
Sanofi (EPA: SAN, NASDAQ: SNY) announced plans to acquire DR-0201, a bispecific myeloid cell engager...
Kexing Biopharm and Hinova Forge Alliance to Expand Global Market Reach
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced this week a strategic alliance with compatriot...
Kintor Pharmaceutical’s KX-826 Shows Promising Results in Alopecia Phase III Trial
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced positive topline results from the long-term safety Phase...
Junshi Biosciences Receives NMPA Approval for JS212 in Advanced Solid Tumors
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced receiving clearance from the...
Hengrui’s Trastuzumab Rezetecan Nears 8th Breakthrough Therapy Designation
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its trastuzumab rezetecan (SHR-A1811), an...
Fosun’s Henlius Receives FDA Orphan Drug Designation for HER2-Targeting HLX22
On March 19, 2025, Fosun Pharmaceutical (SHA: 600196) announced that its subsidiary, Henlius, has received...
Paratek Pharmaceuticals to Acquire Optinose for $330 Million
Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ: OPTN) announced a definitive merger agreement on March 19,...
Boji Medical’s Huasheng Transfers Glucosamine Sulfate Capsules Technology to Panlong
On March 20, 2025, Boji Medical Technology Co., Ltd (known as Boji Biomedicals) (SHE: 300404)...
Oxford BioTherapeutics Partners with Roche on Cancer Therapeutics Discovery
On March 19, 2025, Oxford BioTherapeutics announced a multiyear collaboration with Roche (SWX: ROG, OTCMKTS:...
Joyo Pharma’s JYP0035 Receives Clinical Trial Approval for Breast Cancer Treatment
On March 14, 2025, Joyo Pharma announced that its independently developed next-generation, highly selective Class...
CDE Announces 92nd Batch of Reference Preparations for Generic Drug Evaluation
China’s Center for Drug Evaluation (CDE) has released the 92nd batch of reference preparations for...
HutchMed’s 2024 Financial Report Shows Dip in Revenue Amid Oncology Product Growth
China-based HutchMed (NASDAQ: HCM, HKG: 0013) released its 2024 financial report, revealing a total revenue...
Servier and Black Diamond Therapeutics Ink Global Deal for BDTX-4933
French pharmaceutical company Servier and US-based Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) announced a strategic...